Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must fulfill the following to participate:~* Subject has given his/her written informed consent on an IEC or IRB approved consent form.~* Subject understands the study procedures in the informed consent form (ICF), and is willing and able to comply with the protocol.~* Be either male or female 18 years old~* Have a BMI ≥ 18.5 and ≤ 40.0 kg/m2 at screening~* Is a continuous non-smoker or a smoker who will consume up to 10 cigarettes/day~* Child bearing females should be sexually inactive (abstinent) prior to dosing~* Females subjects of non childbearing potential must have undergone one of the following sterilization or be postmenopausal~Subjects with mild, moderate, or severe hepatic impairment must:~* Have a medical history consistent with a diagnosis of hepatic impairment.~* Have a diagnosis of chronic (\> 6 months), stable hepatic insufficiency~Healthy subjects must be:~* Medically healthy with no significant medical history~Exclusion Criteria:~Subjects must not be enrolled in the study if they:~* Previously participated in any study with tozadenant~* Has orthostatic hypotension, history or symptoms of cardiovascular disease, or hypertensive crisis.~* Currently participating in or has participated in another study and received drug (active or placebo)~* Have a known diagnosis of malignant melanoma~* Have a current episode of major depression~* Has a recent history of suicide attempt~* Has any other condition or clinically significant abnormal findings on the physical or neurological examination, psychiatric and medical history~* Had surgery or any medical condition within 6 months~* Unable to refrain from or anticipates the use of any drugs, vitamins, natural or herbal supplements~* Subject is currently lactating or pregnant or planning to become pregnant.~* Recent donation of blood, plasma or significant blood loss~* Has positive test for ethanol or drugs of abuse or a history of chronic alcohol or drug abuse~* Clinically significant medical history~* Positive results hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) for Healthy Volunteers only.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Subjects (Type: ACTIVE_COMPARATOR): Study dose of 120 mg
- Mild Hepatic Impairment (Type: EXPERIMENTAL): Study dose of 120 mg
- Moderate Hepatic Impairment (Type: EXPERIMENTAL): Study dose of 120 mg
- Severe Hepatic Impairment (Type: EXPERIMENTAL): Up to a maximum study dose of 120 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).